Professor Tomas Kalincik is Dame Kate Campbell Professorial Fellow, the director of the Neuroimmunology Centre at the Royal Melbourne Hospital and the head of the Clinical Outcomes Research (CORe) Unit at the University of Melbourne.

Together with his research group, CORe, Tomas specialises in analytics of observational data in neurology. He has led a number of international collaborative research initiatives - including studies of comparative effectiveness of MS therapies, management of treatment failure and individual treatment response. He has published more than 200 articles in peer-reviewed journals, including JAMA, Lancet Neurology, Lancet Child and Adolescent Health, and Brain. His main research interests span treatment outcomes in MS and other neuroimmunological diseases, personalised therapy, prognostics (including emerging biomarkers), causal inference, epidemiology and harnessing emerging knowledge about the pathogenesis of neuroimmunological conditions to guide individual treatment decisions. He has helped develop instruments, definitions and designs for analysis of observational data. He worked with the MS International Federation and WHO on scoping the first WHO Essential Medicines List for MS. He is an NHMRC Leadership 2 Fellow, the vice-chair of the Scientific Leadership Group of the global MSBase registry, and collaborates with multiple national MS registries. Tomas co-chairs the scientific committee of the MS Australia Progress in MS Research conference, and convenes teaching courses and preceptorships for neurologists, researchers and nurses at the RMH Neuroimmunology Centre.